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Cervical cancer, a potentially preventable disease, has its main aetiology in infection by high risk 
human papillomavirus (HR-HPV). Approaches to improving cervical cancer screening and 10 
diagnostic methodologies include molecular biological analysis, targeting of biomarker proteins, 
but also exploration and implementation of new techniques such as vibrational spectroscopy. This 
study correlates the biomarker protein p16INK4A expression levels dependent on HPV copy number 
with the infrared absorption spectral signatures of the cervical cancer cell lines, HPV negative 
C33A, HPV-16 positive SiHa and CaSki and HPV-18 positive HeLa. Confocal fluorescence 15 
microscopy demonstrated that p16INK4A is expressed in all investigated cell lines in both nuclear 
and cytoplasmic regions, although predominantly in the cytoplasm. Flow cytometry was used to 
quantify the p16INK4A expression levels and demonstrated a correlation, albeit nonlinear, between 
the reported number of integrated HPV copies and p16INK4A expression levels. CaSki cells were 
found to have the highest level of expression, HeLa intermediate levels, and SiHa and C33A the 20 
lowest levels. FTIR spectra revealed differences in nucleic acid, lipid and protein signatures 
between the cell lines with varying HPV copy number. Peak intensities exhibited increasing 
tendency in nucleic acid levels and decreasing tendency in lipid levels with increasing HPV copy 
number, and although they were found to be nonlinearly correlated with the HPV copy number, 
their dependence on p16INK4A levels was found to be close to linear. Principal Component Analysis 25 
(PCA) of the Infrared absorption spectra revealed differences between nuclear and cytoplasmic 
spectroscopic signatures for all cell lines, and furthermore clearly differentiated the groups of 
spectra representing each cell line. Finally, Partial Least Squares (PLS) analysis was employed to 
construct a model which can predict the p16INK4A expression level based on a spectral fingerprint 
of a cell line, demonstrating the diagnostic potential of spectroscopic techniques. 30 
Introduction 
Cervical cancer is a potentially preventable disease and it 
remains the second most common malignancy in women 
worldwide 1. The incidence rates range from less than 15 per 
100,000 in Europe up to 33.5 per 100,000 in Latin America 2. 35 
Many aetiological factors are associated with cervical cancer, 
such as diet, cigarette smoking, multiple sexual partners, 
multiple pregnancies, contraceptive pills, sexually transmitted 
diseases (Chlamydia, HIV) or aging. However, the most 
important factor identified is infection with high risk human 40 
papillomavirus (HR-HPV) 3. There are 15 identified HR-HPV 
types 4 and 70% of all cervical cancers are associated with 
either HPV-16 or HPV-18.  
Differentially expressed proteins in cancer have potential 
utility as biomarkers. As the cell cycle is often disrupted in a 45 
cancerous cell, proteins associated with it are often candidate 
biomarkers. Putative biomarkers of cervical cancer that are 
currently under study include proteins such as CDC 6 (DNA 
licensing protein), minichromosome maintenance proteins 
(MCM 2, MCM 5), p53 or p16INK4A 5. These biomarkers have 50 
been used to detect the presence of abnormal cells, based upon 
immunocytochemical methods.  
p16INK4A regulates the levels of active cyclin D/CDK in the 
cell, providing a feedback mechanism that regulates the levels 
of MCM (minichromosome maintenance proteins), PCNA 55 
(proliferating-cell nuclear antigen) and cyclin E. 
Overexpression of p16INK4A, which is considered a marker of 
elevated E7 expression, can be detected in some CIN1 
(Cervical Intraepithelial Neoplasia grade 1) lesions, as well as 
in CIN2 and CIN3 lesions that show evidence of integration 6-60 
7
. Integration of the HPV genome into the host cell 
chromosome is a critical event in the development of most 
cervical cancers 8. Overexpression of p16INK4A has been 
demonstrated in cervical cancers as a result of functional 
inactivation of pRb by the HPV E7 protein 9. This 65 
overexpression highlights the potential of p16INK4A as a 
marker for CIN and cervical cancer. HPV positivity and 
p16INK4A positivity have shown a correlation, even though 
p16INK4A expression was also seen in a limited number of 
HPV negative biopsy samples 10. Also, a correlation between 70 
p16INK4A expression and cervical lesion grade and HR-HPV 
positivity has been documented 11. p16INK4A has been proven 
to be the most reliable marker of cervical dysplasia and was 
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found to mark all grades of squamous and glandular lesions of 
the cervix. The use of p16INK4A immunocytochemical analysis 
as a complement to conventional screening programmes could 
potentially aid in the reduction of false positive and false 
negative results 12. 5 
In the first part of this study, expression of p16INK4A was 
analysed in cervical cancer cell lines using 
immunocytochemical staining and both confocal fluorescence 
microscopy and flow cytometry. Confocal fluorescence 
microscopy is an optical imaging technique that allows for 10 
high-resolution structural imaging at the cellular level at 
varying depths in the sample while flow cytometry is a well 
established technique for examining and sorting 
fluorochrome-labeled cells, simultaneously providing 
assessment of a multitude of characteristics of individual 15 
cells. 
Four cervical cell lines were used in this study: HPV negative 
C33A, HPV-18 positive HeLa containing 20-50 integrated 
HPV copies per cell, HPV-16 positive CaSki containing 60-
600 integrated HPV copies per cell and SiHa with 1-2 20 
integrated HPV-16 copies per cell.  
The second part of the study utilised Fourier Transformed 
Infrared (FTIR) Spectroscopy to spectroscopically fingerprint 
and differentiate the cervical cancer cell lines. FTIR, along 
with Raman spectroscopy, is a vibrational spectroscopic 25 
technique which provides unique information about the 
chemical composition of a sample. A wide range of biological 
applications, particularly cancer detection, has been reported 
to date 13-19. The development of applications of vibrational 
spectroscopy to medical diagnostics has recently been 30 
reviewed by Diem et al. 20. Significant activity in the area of 
the potential application of FTIR spectroscopy to cervical 
cancer detection has been reported over the last decade 17, 21-
43
. Understanding and processing the biochemical information 
delivered by vibrational spectroscopic techniques and its 35 
correlation with the existing screening and diagnostic methods 
is key to further development of realistic applications of 
Raman and FTIR spectroscopy to cervical cancer detection.   
It has recently been demonstrated that both Raman and FTIR 
absorption spectroscopy can effectively discriminate between 40 
cell lines with varying HPV infection levels 44.  The current 
study explores the potential correlation of spectroscopic 
features with HPV infection levels characteristic of each cell 
line as well as the resultant expression levels of p16INK4 
biomarker.  45 
Materials and Methods 
Cell culture and immunocytochemistry 
Cell lines were obtained from the ATCC cell culture 
collection. All cell lines were grown in RPMI 1640 medium 
(Sigma-Aldrich, Ireland) supplemented with 10% Foetal 50 
Bovine Serum (FBS, BioWhittaker®, Lonza, Ireland), 1% 
Penicillin-Streptomycin (BioWhittaker®, Lonza, Ireland), 1% 
L-glutamine (Sigma-Aldrich, Ireland), and 0.2% 
Hydrocortisone (Sigma-Aldrich, Ireland). Cells were 
incubated at 37°C in 5% CO2 and maintained up to 70-80% 55 
confluency. 
Immunocytochemical staining for p16INK4A was performed on 
each of the cell lines and appropriate negative controls. Cells 
were fixed using 4% paraformaldehyde for 30mins, washed 3 
times with phosphate buffered saline (PBS) and permeabilised 60 
with cold methanol for 10mins. Cells were blocked by 
incubating with blocking buffer (1% bovine serum albumin 
(BSA) in PBS) for 30mins at room temperature with agitation. 
After decanting the serum, cells were incubated for one hour 
at 37°C with the primary antibody, purified mouse anti-human 65 
p16INK4A (BD Pharmingen™, Ireland) in dilution buffer (1% 
BSA in PBS). Following incubation, cells were washed 5 
times with PBS and were incubated with the secondary 
antibody, goat polyclonal to mouse Immunoglobulin G (IgG) 
(Abcam, Ireland) labeled with fluorescein isothyocyanate 70 
(FITC) in dilution buffer. This was carried out in darkness for 
45mins at 37°C. The cells were additionally incubated with 
propidium iodide (PI) staining solution (dilution 1:250) (BD 
Pharmingen™, Ireland) for 15mins and washed 3 times with 
PBS. A negative control was also prepared for each cultured 75 
cell line according the same protocol but with no primary 
antibody (NC1) and no primary or secondary antibody (NC2).  
Sample preparation 
Confocal microscopy 
For confocal microscopy, cells were grown on glass 80 
coverslips in 6 well plates and stained as described above. 
Each coverslip with the stained cells was removed from the 
multi well plate and mounted upside down on a pre-labelled 
glass slide using Sigma diagnostic mounting medium (Sigma-
Aldrich, Ireland). Samples were left to dry in a dark room and 85 
thereafter stored at 4°C until they were examined under the 
confocal microscope.  
Flow cytometry 
Flow cytometry samples were stained as a pellet in Eppendorf 
tubes according to the staining protocol described above. 90 
Pellets were examined directly after the staining procedure. 
FTIR spectroscopy 
Cervical cell lines for FTIR study were grown for 24 hours on 
CaF2 windows. Cells prepared for FTIR study were not fixed 
to avoid contibution of the fixative agent to the cellular 95 
spectra 45. Before FTIR measurements, cells were washed 
twice in PBS and dried to minimise contributions from water.  
Measurements and data handling 
Confocal fluorescence microscopy 
An inverted confocal laser scanning fluorescence microscope 100 
(LSM 510 META, Carl Zeiss) was used to record fluorescence 
images of the cells. The argon ion laser was chosen to excite 
the FITC fluorochromes at 488nm and the HeNe laser was 
used to excite the PI fluorochromes at 543nm. A 63× oil 
immersion objective lens was used for recording. Five to six 105 
images were collected for each sample from different regions 
of the slides.  
Flow cytometry 
A CyFlow® Space Flow cytometer System (Partec) was used 
for the cervical cell analysis. Measurements were performed 110 
for each cell line, represented by 2-4 samples, prepared as 
stained cellular pellets. Fluorescence intensity of the staining 
was calculated based on analysis of approx 2×104 cells for  
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Fig. 1 Confocal microscopy images of cervical cell lines: A-B C33A cells, C-D SiHa cells, E-F HeLa cells, G-H CaSki cells. Images A,C, E and G show 
FITC fluorescence staining (related to p16INK4A expression), while images B, D, F and H present FITC and PI staining. 
each sample. Analysis of the data set was performed using 
FloMax 3.0 software. Gating R1 selected a well defined 5 
population of cells excluding any possible debris present in 
the samples. Gating R2 was performed to exclude doublets 
and triplets of cells analysed by the instrument. The 
subsequent step included applying gating G1 (logical gate of 
R1 and R2) to the investigated fluorescence signal and 10 
choosing the range of interest within which fluorescence 
intensity calculations were performed. 
Infrared spectroscopy 
Fourier Transformed Infrared (FTIR) spectroscopic 
measurements were performed using a Perkin Elmer Spotlight 15 
400 microscope system in transmission mode. The time frame 
between washing the FTIR samples with PBS and start of 
acquiring spectra was 30-40minutes. Spectra were collected as 
an average of 64 scans with a resolution of 2cm-1 using Image 
Mode. FTIR signals were accumulated over a spectral range 20 
of 750 to 4000cm-1. Signals were accumulated with the 
maximal imaging resolution of the system of 6.25µm per 
pixel. The sampling included investigation of two cell culture 
passages prepared on separate slides. Four to five cells per 
slide were analysed.    25 
Spectroscopic data analysis was carried out in Matlab, version 
R2006 (Mathworks, CA, USA) according to protocols 
developed and routinely used in DIT. Processing of the FTIR 
spectra included an EMSC resonant Mie scattering correction 
according to the algorithm developed by Bassan et al. 46 with 30 
the Matrigel spectrum supplied with the algorithm used as 
reference. In the original work, it was demonstrated using 
simulated spectra that the algorithm, which iteratively evolves 
the reference spectrum to fit and correct for both the resonant 
and nonresonant scattering contributions, reproduces the ideal 35 
spectra even using a “non-ideal” reference and that for 
example the true position of the biologically significant 
Amide I band can be obtained with the RMieS-EMSC 
algorithm 46. After pre-processing the spectra, Principal 
Component Analysis (PCA) and Partial Least Squares (PLS) 40 
analysis were performed on the data set. It should be noted 
that, although the spectra were recorded over the range 750-
4000cm-1, the Mie scattering correction was only executable 
over the maximum range of the reference spectrum provided 
with the algorithm, namely 1000-4000cm-1, and thus only this 45 
region is described. 
Results and Discussion 
Confocal microscopy 
Fluorescence images of cells were collected using the 
confocal fluorescence microscopy system. Representative 50 
images of cells are presented in figure 1, where A, C, E and G 
show only green fluorescence staining (FITC), while B, D, F 
and H show the overlay of green (FITC) and red (PI) 
fluorescence signals. The FITC fluorescence intensity is 
associated with the p16INK4A expression level, while the PI 55 
dye was used to visualise the position of nuclei within the 
cells. The fluorescence intensities for the defined FITC 
fluorescence emission wavelengths for the samples stained 
with primary and secondary antibody (p16INK4A staining) and 
NC1 and NC2 samples were compared. The results revealed a 60 
strong emission peak for samples stained with primary and 
secondary antibody and negligible emission for the negative 
control samples (NC1 and NC2) (data not shown). Based on 
these observations, immunostaining was found to be specific 
to p16INK4A . Figure 1 shows that purified mouse monoclonal 65 
anti-human p16INK4A stains both cytoplasmic and nuclear 
regions of the cells, although staining is predominantly in the 
cytoplasm. The presence of p16INK4A in the cytoplasmic 
region may be a result of post transcriptional modification or 
overexpression of the protein, which forces its transfer into 70 
the cytoplasm 12. These findings support previous studies 
confirming the theory that p16INK4A is overexpressed in 
dysplastic cells of the cervix 47. The observations are in very 
good agreement with the work of Klaes et al., who 
demonstrated that the p16INK4A specific immunohistochemical 75 
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Table 1 Quantitative analysis of fluorescence intensity related to p16INK4A expression level and negative control samples with no secondary antibody for 
cervical cancer cell lines obtained from flow cytometry studies. 
  p16INK4A expression Negative controls (NC1) 
Cell line 
Reported number  
of HPV copies  
per cell 
Fluorescence  
intensity 
(a.u.) 
Standard deviation  
for fluorescence intensity 
(a.u.) 
Fluorescence 
 intensity 
(a.u.) 
Standard deviation  
for fluorescence intensity 
(a.u.) 
C33A 0 61.92 1.42 1.32 0.06 
SiHa 1-2 68.14 1.23 1.18 0.08 
HeLa 20-50 80.10 1.92 1.17 0.01 
CaSki 60-600 94.31 1.77 1.41 0.11 
 
a
staining allows for sensitive and specific identification of 
dysplastic cervical cells in cervical cancer tissue sections and 5 
cervical cancer cell lines 48. The results also support the 
findings of Murphy et al., that p16INK4A marks dysplastic 
squamous and glandular cells of the cervix with a sensitivity 
of 99.9% and specificity of 100% 49. The negative HPV cell 
line C33A was p16INK4A positive (figure 1A-B), but exhibited 10 
the lowest staining intensity of the investigated cell lines. This 
finding confirms the previous study of Milde-Langosch et al. 
in which p16INK4A overexpression was reported in 41% of 
HPV negative adenocarcinomas and it was suggested that a 
non-HPV E7 mediated mechanism of p16INK4A up regulation 15 
may also exist 50.  
Quantitative analysis of the fluorescence intensity of FITC 
visible in the confocal images, albeit on a limited number of 
individual cells, indicated that there is a correlation between 
the number of integrated HPV copies per cell and p16INK4A 20 
expression characteristic to each cell line. CaSki cells were 
found to have the highest intensity of staining, with 
decreasing tendency for HeLa and SiHa and C33A expressing 
the lowest intensity (data not shown).  
Flow cytometry  25 
To more precisely quantify expression of p16INK4A protein in 
cervical cancer cell lines, flow cytometry measurements were 
performed to enable a larger statistical basis. For all the 
investigated cell lines, the populations were well defined, 
allowing for a precise investigation of the cells of interest.  30 
Mean fluorescence intensity levels related to p16INK4A 
expression are presented in table 1 together with their 
standard deviations. Values of fluorescence intensity for 
negative control (NC1) samples prepared for the investigated 
cell lines according to the immunostaining protocol but with 35 
no primary antibody are also presented in table 1. Values of 
fluorescence intensities for NC1 were lower than the standard 
deviations for fluorescence intensities related to p16INK4A 
expression, confirming that the flow cytometry analysis was 
specific to p16INK4A. A degree of correlation between the 40 
number of HPV copies per cell line and the fluorescence 
intensity related to p16INK4A expression was observed for the 
flow cytometry data (figure 2). The highest level of p16INK4A  
expression (intensity of staining) was observed for CaSki 
cells, followed by HeLa, SiHa and the lowest for C33A. The 45 
relationship between p16INK4A expression and HPV copy 
number illustrated by figure 2 is supported by a study  
 
Fig. 2 Fluorescence intensity related to the p16INK4A expression level in 
cervical cancer cell lines plotted against the average HPV copy number 50 
present in a cell with the fitted function.  The dotted line is a fit of the data 
with the equation y=a+b√x +cx, where a=62.4, b=3.5 and c=-0.1. 
conducted by Klaes et al., wherein a correlation between 
increasing grade of cervical lesion and staining intensity of 
p16INK4A was observed 48. Similarly, Agoff et al. showed that 55 
p16INK4A expression correlates with an increasing severity of 
cervical disease 51. Murphy et al. showed a strong correlation 
between HR-HPV positivity and p16INK4A staining pattern 12, 
52-53
. In the study conducted by Wang et al. a correlation 
between p16INK4A immunostaining and cervical disease 60 
severity stratified by HPV status was observed 54. The results 
in the present study demonstrate a correlation between  
 
Fig. 3Visual images (A-D) and average absorbance FTIR maps (E-H) 
representing cells present in the investigated samples. A and E – C33A 65 
cell, B and F – SiHa cells, C and G – HeLa cells, D and H – CaSki cells. 
Red colour represents region of a nucleus, green and light blue – region of 
a cytoplasm, violet – background. 
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Table 2. Assignments 55 of FTIR bands of cellular spectra recorded from cervical cancer cells. Wavenumbers in brackets are attributed to peaks 
characteristic of cytoplasmic spectra that were noticed to be shifted with respect to peaks corresponding to nuclear constituents.  
Peak no. 
Wavenumber 
(cm-1) 
Assignment Proteins Lipids Nucleic acids 
I 1036 C-C skeletal stretching +   
II 1070 (1082) symmetric PO2 str. mode   DNA, RNA 
III 1120 C-O stretching   RNA 
IV 1170 CO-OC asymmetric stretching +   
V 1240 Amide III , asymmetric PO2 str. mode +  DNA, RNA 
VI 1310 (1316) CH2 stretching  +  
VII 1400 CH3 symmetric deformations +   
VIII 1450 CH3 asymmetric deformations + +  
IX 1550 C-N stretching and CHN bending -Amide II +   
X 1650 C=O stretching - Amide I +   
XI 2854 CH2 symmetric stretching  +  
XII 2875 CH3 symmetric stretching  +  
XIII 2926 CH2 asymmetric stretching  +  
XIV 2962 CH3 asymmetric stretching  +  
XV 3292 (3300) N-H stretching (Amide A) +  DNA, RNA 
a
p16INK4A immunostaining and the presence of HR-HPV in 
cervical cancer cell lines supporting the previous studies and 5 
implies that p16INK4A is a highly sensitive marker of HR-HPV in 
cervical cancer cell lines. The hyperbolic-like relationship 
between the levels of p16INK4A  and HPV copy number is typical 
of the response of a cell to the action of an agonist 56 and in figure 
2, is approximated by a fit with the following function y=a+b√x 10 
+cx, where a=62.4, b=3.5 and c=-0.1. It should be noted that, in 
figure 2, the HPV copy number is represented by the average of 
the range quoted in literature 57-58 and so error margins in the 
horizontal axis are potentially very large. However, the sublinear 
nature of the plot indicates that p16INK4A expression levels are 15 
particularly sensitive for low HPV copy number. 
FTIR spectroscopy 
FTIR maps were recorded for C33A, SiHa, HeLa and CaSki 
cells (2-4 maps for each cell line) using the Perkin Elmer 
Spotlight 400 system. Representative images are presented in 20 
figure 3 (A-D). Representative unprocessed FTIR maps, 
generated by the Spectrum Image software, showing 
spectrally averaged absorbances, recorded from the regions of 
interest within the investigated samples are shown in figure 3, 
E, F, G and H, for C33A, SiHa, HeLa and CaSki, respectively. 25 
Nuclear and cytoplasmic regions are well defined, due to their 
varying density and thickness, in the FTIR maps. Spectra 
representing nuclear and cytoplasmic regions of the cells were 
extracted from the FTIR maps using the Perkin Elmer 
Spectrum IMAGE software and delivered mean spectra of 30 
cellular structures characteristic of the cell lines (figure 4). 
Spectra extracted from the maps were chosen from the middle 
of the nucleus or cytoplasm. As a result, from 60-80 spectra 
recorded for one cell, only a few of them were used in the 
analysis. This procedure ensured that only nuclear or 35 
cytoplasmic signals were compared rather than a mix of the 
cellular signatures. Each spectrum from figure 4 was  
 
Fig. 4 Mean FTIR spectra of cervical cancer cell lines representing 
regions of cells (nucleus and cytoplasm). 40 
calculated as an average of 30-40 signals extracted from the 
FTIR maps characteristic of the defined cellular structure and 
was subjected to pre-processing using the RMieS-EMSC 
algorithm. Assignments of the main FTIR bands (numbered in 
figure 4) are presented in table 2. Three main biochemical 45 
cellular components feature strongly: proteins, lipids and 
nucleic acids. For all cell lines, the nuclear and cytoplasmic 
regions exhibited similar FTIR bands related to the vibrations 
of these constituent components. There were, however, 
differences in the band intensities. A distinctive reduction of 50 
lipids was noticed in the IR signal of the cytoplasm compared 
to the signal of the nucleus, manifest in the CH2 and CH3 
groups stretching bands in the range of 2850cm-1 – 2970cm-1, 
due to the double lipid bilayer nuclear envelope, compared to 
the phospholipid bilayer membrane of the cytoplasm. 55 
Furthermore, the peak at 1120cm-1 is present only in the 
cytoplasm. This feature is related to vibrations of RNA 
components, which are mainly present in the cytoplasmic 
organelles. Three peaks related to cytoplasmic constituent  
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Fig. 5 Peak intensity analysis for FTIR spectra of nuclear and cytoplasmic regions of cervical cancer cells. Dependence of peak intensities vs. HPV copy 
number was fit with y=a+b√x +cx function, while peak intensities vs. fluorescence intensities (p16INK4A expression level) was fit with a linear function, 
y=a+bx. 
vibrations were also noticed to be shifted to higher 5 
wavenumbers (1082cm-1, 1316cm-1, 3300cm-1) compared to 
nuclear bands related to the same types of vibration (1070cm-
1
, 1310cm-1, 3292cm-1). A detailed examination of the relative 
intensities of peaks related to vibrations of the cellular 
components (nucleus and cytoplasm) of the C33A, SiHa, 10 
HeLa and CaSki infrared spectra revealed the following 
tendencies: 
• Increase in nucleic acid levels with increasing 
number of HR-HPV copies in the cell or increasing 
p16INK4A expression (figure 5A, 5D), 15 
• Decrease in lipid levels with increasing number of 
HR-HPV copies in the cell or increasing p16INK4A 
expression (figure 5B, 5E), 
• No tendency for changes in protein levels related to 
HR-HPV copy number or increasing p16INK4A 20 
expression (figure 5C, 5F). 
As the RMieS-EMSC correction uses the protein based 
Matrigel as a reference and effectively normalises the protein 
levels, the third observation is not surprising, and variations in 
nucleic acids and lipid related features should be considered 25 
relative to the protein levels. 
The observed increase in nucleic acid levels may be related to 
an increased number of chromosomes present in HPV infected 
nuclei. It was reported by Mehés et al. that HPV presence 
facilitates polyploidisation (increase in chromosome number 30 
in a cell nucleus) in cervical squamous cells 59. Additionally, 
it is known that binding of HPV DNA to host DNA disrupts  
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Fig. 6  Principal component analysis results. A – scatterplots presented in 
three and two dimensional form, B – principal component loadings with 
marked regions of the main biocomponent contribution. 
the normal function of the cellular proteins and as a 5 
consequence, the host cell accumulates more and more 
damaged DNA that cannot be repaired 60.  
CaSki cells are known to be the most malignant and in the 
spectra of the cytoplasm and nucleus representing this cell 
line the highest level of nucleic acids was observed. A similar 10 
increase of the nucleic acid related peaks in cancerous 
cervical cells was noticed in previous studies 33, 42 and is 
confirmed by these observations. Changes in lipid levels are 
possibly associated with the disruption of the membrane 
functionality caused by the virus which influences lipid rafts 15 
61
. A similar behaviour was noted and reported in our previous 
study on cervical cancer cell lines, wherein both Raman and 
FTIR (point mode) techniques were utilised 62. Moreover, it 
was reported previously by Wong et al. that the degree of 
disorder of methylene chains in membrane lipids increases in 20 
cervical neoplastic cells 63. The absence of any clear 
relationship between protein levels and HPV copy number is 
expected, as the presence of HR-HPV in the cell results in 
functional over- and under- expression of only select 
biomarker proteins 5, while the level of the other proteins 25 
would not be affected. The variation of the spectroscopic 
features associated with the nuclear lipids, proteins and 
nucleic acids as a function of the HPV copy number was 
found to be sublinear and to be well fitted with a similar 
function to that employed to describe the variation of the 30 
p16INK4A levels with HPV copy number in figure 2. Notably, 
the dependences of the cytoplasmic lipids, proteins and 
nucleic acids on the p16INK4A levels, as identified by 
fluorescence were found to be linear.  
 35 
Principal Component Analysis 
Figure 6 shows the results of Principal Component Analysis 
(PCA) of the spectral data for the four cell lines. The analysis 
clearly differentiates between nuclear and cytoplasmic FTIR 
signals for each cell line. The percentage variance explained 40 
by the first three principal components was 88.34%, 4.44% 
and 2.23% for PC1, PC2 and PC3, respectively. The PCA 
scatterplot (figure 6A) reveals that the cytoplasm spectra of 
C33A and SiHa are close to each other, suggesting similarities 
in cytoplasmic composition of these cell lines. However, in 45 
terms of the nuclear data, the cell lines are very well 
separated. C33A are HPV negative, while SiHa contain a very 
low number of integrated HPV copies per cell (1-2). HPV 
DNA and host cell DNA integration occurs within the nucleus 
of a cell. Thus, the differences between C33A (HPV negative 50 
- no integration) and SiHa (HPV positive - integration) at the 
nuclear level are understandable. It is possible, that in the 
cytoplasm, biochemical changes in the cell affected by a very 
low number of HPV copies are not as prominent as in the 
nucleus. In the case of cells infected by 20-50 HPV copies 55 
(HeLa) and 60-600 copies (CaSki), biochemical changes 
within the cytoplasm become more prominent resulting in, for 
example, a stronger under- and overexpression of cytoplasmic 
proteins. Thus the cytoplasmic signals of C33A and SiHa are 
distributed close to each other, while HeLa and CaSki are very 60 
well separated. In general, the clusters representing the 
spectra of cytoplasm are more dispersed than those 
corresponding to cell nuclei. This could be explained by the 
fact that the cytoplasm is much more variable in its 
composition compared to the nucleus, therefore exhibiting 65 
more variation in the FTIR signals. Although, the Resonant 
Mie scattering correction algorithm cannot be considered 
perfect as evidenced by the incomplete baseline correction in 
the loadings plots of the PCs, (figure 6B), it is considered the 
most effective method currently available allowing for 70 
removing the Mie scattering influence from the FTIR signals. 
The separation between the nuclear and the cytoplasmic 
clusters is clearly due to the first principal component (PC1). 
Based on the PC1 loading (figure 6B), it can be concluded 
that the biochemical variability between these two cellular 75 
components primarily arises from the lipid levels (region of 
2800-3000cm-1). In PC1, protein contributions are also 
notable (1400-1700cm-1, 3000-3500cm-1). PC1 also shows 
nucleic acid variations (1050-1200cm-1), the symmetric 
phosphodiester group stretching band in RNA (peak at 80 
1120cm-1) being strongly accented in cytoplasm spectra. This 
observation is consistent with the mean spectra analysis, 
whereby the peak at 1120cm-1 was seen to be prominent in the 
spectra of the cytoplasm of all cell lines and absent in the 
signals from nuclei (figure 4 – peak III in enlarged nucleic 85 
acid region). PC2 indicates a high variability of the proteins 
(Amide I, Amide II, Amide III, Amide A). This separation of 
the cell lines confirms the study of Kelly et al., where amide 
bands were also determined to be a source of differentiation of 
the cervical cancer cells 27. In PC2 there is also a lipid 90 
contribution present originating from symmetric and 
asymmetric vibrations of the CH2 and CH3 groups. A two 
dimensional representation of the scatterplot PC1 vs. PC2 
(figure 6A) shows that the internal variability of the 
cytoplasm signals is extended along PC2. Therefore, it can be 95 
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Fig. 7 Partial Least Squares analysis results targeting the p16INK4A 
expression level prediction based on the FTIR spectral features. 
concluded that it originates mainly from variations in the 
protein levels within the cell. Groups of points in the PCA 5 
scatterplot representing the spectroscopic signatures of C33A, 
SiHa, HeLa and CaSki cell lines recorded from nuclei are 
separated along the third principal component. In PC3 
contributions of all components are present; nucleic acids, 
lipids and proteins. This illustrates that the HR-HPV infection 10 
influences the entire biochemistry of the cell through a chain 
of reactions 64.   
Partial Least Squares Analysis 
In order to further elucidate the multivariate spectral 
signatures which are specifically related to HPV infection, 15 
Partial Least Squares (PLS) analysis was performed. Figure 5 
demonstrates that p16INK4A levels as measured by fluorescence 
intensity are approximately linearly correlated with the 
univariate spectral features and thus, as PLS is a linear model, 
these values are employed as targets for the PLS analysis. The 20 
model can therefore be applied to the FTIR data to elucidate 
multivariate signatures which are correlated to p16INK4A 
expression level, and therefore, in accordance with figure 2, to 
HPV infection levels. Once established, these variation 
patterns can then be applied to unknown samples to screen for 25 
the biomarker levels. As p16INK4A was found to be 
predominantly expressed in cytoplasmic regions of the cells, 
signals recorded from the cytoplasm were utilised in the 
analysis. Calibration (based on 40% of the data) and test set 
performance (based on 60% of the data) are presented in 30 
figure 7A and demonstrate a very good fit to the model. As 
shown in figure 7B, the PLS loading exhibits variations 
originating from proteins, primarily as sub-bands of Amide A 
(3000-3700cm-1) and Amide III (1230-1250cm-1), and are 
associated with the chain of biochemical disruption in protein 35 
regulation caused by HPV presence 64Another prominent 
spectral feature differentiating the cell lines, and present in PC 
loadings and the PLS loading, is the lipid contribution. Again, 
the presence of HR-HPV is seen to significantly influence the 
lipid balance within the cell 61, and thus it can be expected 40 
that the vibrations of lipid component groups differentiate 
cells with various HPV copy number. This differentiation was 
distinctly manifest in the mean spectra of the cytoplasm and 
nucleus (figure 4 – enlarged lipid region of 2800-3050cm-1).  
Furthermore, the DNA and RNA related peaks are exhibited 45 
in the range of 1050-1250cm-1,(sym. and asym. PO2 str. CO 
str.) and 3200-3400cm-1. Such activity in the region of the 
nucleic acid features is consistent with the profile of PC1 and 
PC3 (figure 6B), which differentiates the cell line signals, and 
as a consequence distinguishes cells as a function of HPV 50 
copy number. 
Conclusions 
Confocal fluorescence microscopy and flow cytometry 
revealed that p16INK4A expression levels were correlated with 
HPV infection levels in cervical cancer cell lines. This 55 
confirms p16INK4A as a potential diagnostic marker of cervical 
cancer, supporting the results of many other studies 47-48, 65. 
Integration of HR-HPV sequences into the cell genome is 
considered to be an important event in the progression of 
cervical neoplasia. In this study, a correlation between the 60 
integrated HPV copy number and intensity of p16INK4A was 
observed. FTIR imaging allowed for identification of the 
specific spectral features of nuclear and cytoplasmic regions 
of the cervical cancer cells, indicating the differences between 
the two, in terms of lipid and RNA levels. PCA analysis 65 
revealed that the spectral analysis clearly separates the nuclear 
and cytoplasmic characteristic signals, and additionally 
distinguishes the cell lines. At low copy number, HPV 
predominantly influences the nucleus of the cell, whereas 
increased copy number impacts on the cytoplasmic signatures. 70 
A model of p16INK4A expression level prediction based on 
FTIR spectroscopy was constructed utilising PLS analysis. 
Modelling was predominantly based on spectral features 
arising from nucleic acid, lipid and protein contributing 
features, which are influenced by the HPV interaction with the 75 
host cell. Notably, this work proves that the wavenumbers 
above 2700cm-1 may exhibit crucial information. This region 
of the FTIR spectrum has been neglected in many studies 
conducted on biological samples.  
A potential application of vibrational spectroscopy to cervical 80 
cancer screening and diagnosis requires a full understanding 
of the spectral information and its correlation with existing 
screening and diagnostic methods such as Pap testing or 
colposcopy. However, the field of the cervical cancer 
recognition and detection is still developing with new 85 
biomarkers 5 being identified that may be considered  as 
adjuncts to existing cervical cytology and pathology 
methods. Biomarkers such as p16INK4A have been found to be 
useful for low-grade lesions 66-69 making them particularly 
attractive. Thus, a correlation and explanation of the spectral 90 
information with these new biomarkers is a new challenge for 
biospectroscopists working on future cancer diagnostic 
systems. 
 This journal is © The Royal Society of Chemistry [year] Journal Name, [year], [vol], 00–00  |  9 
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